{"id":"abiraterone-acetate-standard-dose","safety":{"commonSideEffects":[{"rate":"27%","effect":"Fatigue"},{"rate":"21%","effect":"Hypertension"},{"rate":"18%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Abiraterone acetate is a CYP17 inhibitor that blocks the production of androgens, such as testosterone, which are involved in the growth and spread of prostate cancer cells.","oneSentence":"Inhibits CYP17, an enzyme involved in the production of androgens.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T02:20:21.512Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prostate cancer"}]},"trialDetails":[{"nctId":"NCT05593497","phase":"PHASE2","title":"A Single-Arm Phase II Study of Neoadjuvant Intensified Androgen Deprivation (Leuprolide and Abiraterone Acetate) in Combination With AKT Inhibition (Capivasertib) for High-Risk Localized Prostate Cancer With PTEN Loss","status":"RECRUITING","sponsor":"VA Office of Research and Development","startDate":"2024-05-31","conditions":"High-Risk Prostate Cancer","enrollment":30},{"nctId":"NCT06457919","phase":"PHASE1, PHASE2","title":"A Study of Tinengotinib (TT-00420) in Combination With Standard Treatments in People With Prostate Cancer","status":"RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2024-06-04","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT04597125","phase":"PHASE4","title":"RADIANT: A Study of Radium-223 Dichloride (Xofigo) vs Enzalutamide or Abiraterone (ARPIs, Androgen Receptor Pathway Inhibitors) in Patients With Prostate Cancer That Has Spread to the Bones (mCRPC, Metastatic Castration-Resistant Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Bayer","startDate":"2020-11-09","conditions":"Metastatic Castrate Resistant Prostate Cancer (mCRPC)","enrollment":654},{"nctId":"NCT05137262","phase":"PHASE2","title":"A Phase II Multicenter Study of Chemotherapy Versus Chemotherapy Plus Durvalumab (MEDI 4736) in Patients With Lymph Node Positive Urothelial Carcinoma of the Bladder","status":"ACTIVE_NOT_RECRUITING","sponsor":"M.D. Anderson Cancer Center","startDate":"2021-10-13","conditions":"Urothelial Carcinoma, Bladder Cancer","enrollment":12},{"nctId":"NCT07389174","phase":"EARLY_PHASE1","title":"Safety and Efficacy Evaluation of LC-K76 in Patients With Metastatic Hormone-Sensitive Prostate Cancer","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Changzheng Hospital","startDate":"2026-02","conditions":"mHSPC, mHNPC, Prostate Cancer Adenocarcinoma","enrollment":40},{"nctId":"NCT06384222","phase":"PHASE2","title":"Hyperpolarized (HP) 13C Pyruvate Magnetic Resonance Imaging (MRI) for Response Monitoring to Neoadjuvant Abiraterone","status":"RECRUITING","sponsor":"Ivan de Kouchkovsky, MD","startDate":"2024-12-09","conditions":"High Risk Prostate Carcinoma, Prostate Cancer","enrollment":32},{"nctId":"NCT03833921","phase":"PHASE2","title":"Evaluation of Response to Abiraterone/Prednisone by Race/Ethnicity and Other Factors in Metastatic Hormone Naive Prostate Cancer","status":"RECRUITING","sponsor":"Martha Mims","startDate":"2019-05-23","conditions":"Prostate Cancer Metastatic, Prostate Cancer","enrollment":130},{"nctId":"NCT03007732","phase":"PHASE2","title":"Pembrolizumab +/- SD-101 in Hormone-Naïve Oligometastatic Prostate Cancer With RT and iADT","status":"COMPLETED","sponsor":"David Oh","startDate":"2017-05-17","conditions":"Prostatic Neoplasms","enrollment":23},{"nctId":"NCT07164794","phase":"PHASE2","title":"Memantine Hydrochloride in Prostate Cancer Patients","status":"NOT_YET_RECRUITING","sponsor":"Bin Xu","startDate":"2025-11","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Prostate Cancer, Neuroendocrine Prostate Cancer (NEPC)","enrollment":15},{"nctId":"NCT02574910","phase":"PHASE1","title":"Androgen Reduction in Congenital Adrenal Hyperplasia, Phase 1","status":"TERMINATED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2017-08-01","conditions":"Congenital Adrenal Hyperplasia","enrollment":4},{"nctId":"NCT06060587","phase":"PHASE2","title":"Randomized Phase II Study of ADT + Abiraterone vs ADT + Docetaxel + Abiraterone","status":"WITHDRAWN","sponsor":"Northwestern University","startDate":"2023-10-19","conditions":"Prostate Cancer","enrollment":""},{"nctId":"NCT06392841","phase":"PHASE2","title":"Niraparib, Abiraterone Acetate and Prednisone for mHSPC With Deleterious Homologous Recombination Repair Alterations","status":"WITHDRAWN","sponsor":"Qian Qin","startDate":"2025-10","conditions":"Metastatic Hormone-sensitive Prostate Cancer (mHSPC), Deleterious HRR Gene Mutation, BRCA1 Gene Mutation","enrollment":""},{"nctId":"NCT06320067","phase":"PHASE3","title":"A Randomised Controlled Platform Trial Testing Treatments in Metastatic Hormone Sensitive Prostate Cancer","status":"RECRUITING","sponsor":"University College, London","startDate":"2024-06-11","conditions":"Prostate Cancer Metastatic","enrollment":3360},{"nctId":"NCT03458247","phase":"PHASE2","title":"Study of Dose Escalation of Abiraterone Actetate in Prostate Cancer","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2018-06-22","conditions":"Prostate Cancer","enrollment":94},{"nctId":"NCT03170960","phase":"PHASE1","title":"Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Exelixis","startDate":"2017-09-05","conditions":"Urothelial Carcinoma, Renal Cell Carcinoma, Non-Small Cell Lung Cancer","enrollment":914},{"nctId":"NCT01688492","phase":"PHASE1, PHASE2","title":"Combining Ipilimumab With Abiraterone Acetate Plus Prednisone in Chemotherapy and Immunotherapy-naïve Patients With Progressive Metastatic Castration-resistant Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2012-09","conditions":"Prostate Cancer","enrollment":54},{"nctId":"NCT05288166","phase":"PHASE3","title":"A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2022-04-14","conditions":"Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms","enrollment":925},{"nctId":"NCT03706365","phase":"PHASE2, PHASE3","title":"A Study of Abiraterone Acetate Plus Prednisone With or Without Abemaciclib (LY2835219) in Participants With Prostate Cancer","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2018-11-26","conditions":"Prostate Cancer","enrollment":393},{"nctId":"NCT03903835","phase":"PHASE3","title":"ProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer","status":"RECRUITING","sponsor":"Karolinska Institutet","startDate":"2019-02-01","conditions":"Metastatic Castration-resistant Prostate Cancer (mCRPC), Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)","enrollment":750},{"nctId":"NCT06329830","phase":"PHASE1, PHASE2","title":"177Lu-PSMA, Niraparib/AA Plus Prednisone for Prostate Cancer","status":"WITHDRAWN","sponsor":"Baptist Health South Florida","startDate":"2024-10","conditions":"Metastatic Prostate Cancer, Castration-resistant Prostate Cancer, Metastatic Castration-resistant Prostate Cancer","enrollment":""},{"nctId":"NCT02740985","phase":"PHASE1","title":"A Phase 1 Clinical Study of AZD4635 in Patients With Advanced Solid Malignancies","status":"COMPLETED","sponsor":"AstraZeneca","startDate":"2016-06-17","conditions":"Advanced Solid Malignancies, Non-Small Cell Lung Cancer (NSCLC), Metastatic Castrate-Resistant Prostate Carcinoma (mCRPC)","enrollment":313},{"nctId":"NCT04356430","phase":"PHASE2","title":"Neoadjuvant Therapy of Abiraterone Plus ADT for High Risk Prostate Cancer","status":"UNKNOWN","sponsor":"The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School","startDate":"2019-04-01","conditions":"Prostate Cancer","enrollment":75},{"nctId":"NCT01681433","phase":"PHASE2","title":"OGX-427 in Metastatic Castrate-Resistant Prostate Cancer With Prostate-Specific Antigen Progression While Receiving Abiraterone","status":"TERMINATED","sponsor":"Costantine Albany","startDate":"2012-12","conditions":"Prostate Cancer, Metastatic Castrate-Resistant Prostate Cancer, PSA","enrollment":72},{"nctId":"NCT04296578","phase":"PHASE1","title":"Study Evaluating Sodium Selenite in Combination With Abiraterone in Castrate Resistant Prostate Cancer Progressing on Abiraterone","status":"WITHDRAWN","sponsor":"Stanford University","startDate":"2020-10","conditions":"Prostate Cancer, Castrate Resistant Prostate Cancer","enrollment":""},{"nctId":"NCT04736108","phase":"PHASE2","title":"Neoadjuvant Therapy of Abiraterone Plus ADT for Intraductal Carcinoma of the Prostate","status":"UNKNOWN","sponsor":"West China Hospital","startDate":"2021-05","conditions":"Prostate Cancer","enrollment":50},{"nctId":"NCT02730975","phase":"PHASE1","title":"Pharmacokinetic Food-effect Study of Abiraterone Acetate (AA) in Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Fundación Pública Andaluza para la gestión de la Investigación en Sevilla","startDate":"2014-05-12","conditions":"Prostate Cancer","enrollment":42},{"nctId":"NCT01637402","phase":"PHASE2","title":"A Phase II Study of Increased-Dose Abiraterone Acetate in Patients With Castration Resistant Prostate Cancer","status":"COMPLETED","sponsor":"Terence Friedlander, MD","startDate":"2013-03-13","conditions":"Castration Resistant Prostate Cancer","enrollment":41},{"nctId":"NCT01717898","phase":"PHASE1, PHASE2","title":"A Multicenter Phase I/II Trial of Abiraterone Acetate + BEZ235 in Metastatic, Castration-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"Charles Ryan","startDate":"2013-01-31","conditions":"Castrate-resistant Prostate Cancer","enrollment":6},{"nctId":"NCT01913015","phase":"PHASE1","title":"Dietary Fat Levels and Abiraterone Acetate Uptake in Patients With Metastatic Hormone-Resistant Prostate Cancer","status":"TERMINATED","sponsor":"OHSU Knight Cancer Institute","startDate":"2013-07","conditions":"Adenocarcinoma of the Prostate, Hormone-resistant Prostate Cancer, Recurrent Prostate Cancer","enrollment":3}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":10,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"Abiraterone acetate standard dose","genericName":"Abiraterone acetate standard dose","companyName":"Assistance Publique - Hôpitaux de Paris","companyId":"assistance-publique-h-pitaux-de-paris","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits CYP17, an enzyme involved in the production of androgens. Used for Prostate cancer.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}